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1. Introduction
  Ventricular septal defect (VSD) is the most common 
(approximately 20%) congenital heart disease[1]. Long-term follow-
up studies have shown that transcatheter closure of VSD, which as a 
feasible alternative to surgery, has been commonly recommended[2]. 
Taking into account the increasing of potential risk of AR 
aggravation, device closure of patients with VSD companied with 
AVP and AR still represents a challenging issue. Moreover, there 
is little clinical data available in the literature about the feasibility 
and safety of this procedure for such patients. In this article, we 
summarize our experience of transcatheter closure technique and 
report initial follow-up outcome of feasibility, safety and efficacy in 
65 patients.
2. Materials and methods 
2.1. Device  
  The HeartR™ VSD Occluder (Lifetech Scientific (Shenzhen) 
Corporation, P.R.C) has been thoroughly described previously[3]. 
It is a self-expandable, double disc device made from a Nitinol 
wire mesh. The two discs are linked together by a short cylindrical 
waist corresponding to the size of the VSD. The discs and waist 
are filled with PTFE membranes eccentric sewn to the device by 
Nylon threads. The device is loaded into a 6-8F delivery sheath. 
Asymmetric occluder (Figure 1) was selected in accordance with 
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the anatomical conditions and pathophysiological types in patients 
with valve prolapse (AVP) and aortic regurgitation (AR).
 
Figure 1. Schematic diagram of VSD membranous asymmetric occluder.
2.2. Patient population
  Between January 2008 and July 2014, 65 patients underwent an 
attempt of transcatheter closure of VSDs. Subjects had indications 
for transcatheter closure of VSD associated AVP and mild AR were 
verified by transthoracic and transesophageal echocardiography 
(TTE) was included. Patients with infective endocarditis, right 
to left shunt, sepsis, complex heart lesions require surgery or 
contraindication to antiplatelet therapy were excluded. The patients 
ranged in age from 3 years to 14 years [(6.01依3.05) years] and 
in weight from 13.2 kg to 38.9 kg [(24.9依11.3) kg]. The mean 
subaortic rim was 3.7 mm, with a range of 3 mm to 5 mm. The 
mean VSD diameter was 4.9 mm, with a range of 4 mm to 7 mm. 
Perimembranous VSD (pmVSD) was present in 18 (27.7%) patients 
and intracristal VSD (icVSD) was noted in 47 (72.3%) patients 
respectively. Membranous aneurysms were present in 29 (44.6%) 
patients. The mean pulmonary to systemic flow ratio (Qp/Qs) was 
1.9:1, with a range of 1.6:1 to 2.2:1. The VSD diameter evaluated by 
TTE was 4.9 mm, with a range of 4 mm to 7 mm. The Biomedical 
Research Ethics Committee of Hainan General Hospital had 
approved the study and all subjects or their guardians had signed a 
written informed consent to undergo the transcatheter procedures. 
The clinical characteristics of patients are summarizes in Table 1.
2.3. Preprocedural echocardiography
  All patients were evaluated by TTE in the apical five-chamber view 
and long axis parasternal view to evaluate the diameter of VSD and 
rim under the aortic valve, then in the short axis parasternal view 
the type of VSD and anatomical location were detected. Inclusion 
criteria of patients as follows: (i) pmVSD diameter < 12 mm or ic 
VSD diameter < 10 mm; (ii) mild aortic regurgitation is confirmed 
by TTE.
2.4. Implantation procedures
  All patients were administered with 80-100 IU/kg heparin 
and antibiotics prophylaxis intravenously before the procedure. 
Procedures were performed under local anesthesia, while children 
aged<10 years were under general anesthesia and guided under 
fluoroscopic (Figure 2) and TTE (Figure 3). The protocol used has 
been described in detail in previous reports[4]. Briefly, access was 
obtained through the right femoral artery and vein. Routine right and 
left cardiac catheterization and standard left ventricular angiography 
were undergone in all cases to calculate again the diameter, 
pathophysiological type and anatomical location of the VSD. Then, 
a wire was positioned into the pulmonary artery followed by placing 
a sheath. Catheter was then positioned in the pulmonary artery 
through this sheath. The wire was snared from the pulmonary artery 
and forming a femoral artery- left ventricle-defect-femoral vein loop. 
Once this loop was established, the delivery sheath was advanced 
over this wire and positioned in the left ventricle. Once the sheath 
was confirmed in good position, device placement was performed as 
usual. The appropriate device size was chosen to be at least 1 mm to 
2 mm larger than the defect size as measured. If significant residual 
shunts still existed or the device was easy to dislodge after attempted 
closure of the defect using the above size device, we further tried 
to close with a larger size device (2-4 mm larger than the defect). 
Oral aspirin 3-5 mg/kg daily was administered for patients was 
recommended.
Table 1 
Clinical characteristics of patients.
Male/Female 38/27
Age (yrs) 6.01 (3-14)
Weight (kg) 24.9 (13.2 -38.9)
TTE
pmVSD (n, %)    18 (27.7%)
icVSD (n, %)    47 (72.3%)
Subaortic rim (mm)   3.7 (3-5)
VSD diameter (mm)   4.9 (4-7)
Rim from the tricuspid to the defect (mm)   3.6 (2 -5)
Membranous aneurysms (n, %)    29 (44.6%)
Catheterization
VSD diameter (mm)   5.2 (5 -7)
Qp/Qs   1.9 (1.6-2.2)
PA systolic pressure (mmHg)   33 (28-40)
PA mean pressure (mmHg)   17 (13-21)
Severity of AVP
     Grade 栺 (n, %)   43 (66.2%)
     Grade 栻(n, %)   20 (30.7%)
     Grade栿 (n, %)     2 (3.0%)
Device diameter (mm)  7.3 (5-10)
 
Figure 2. Illustration of the various steps of closure by fluoroscopy, 
respectively. 
(A) LV angiogram showing the mVSD. (B) Same view as (A) demonstrating 
showing the arteriovenous loop. (C) Left ventricular disk has been deployed. 
(D) Cine image immediately after the whole occluder has been deployed. (E) 
Left ventriculography showing no residual shunt. (F) Final LV angiogram 
same view as (A) showing good device position and complete closure.
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Figure 3. Comparison of severity of AR that as seen on a modified apical 
five-chamber view  in early diastole.
(A)before procedure (arrow); (B) immediately after occluder retrieved 
(arrow).
2.5. Data collection and follow-up
  Immediate procedure success was defined by device release 
and fixed in the appropriate position without residual shunt and 
aggravation of device-related aortic regurgitation. Perioperative 
data of complications were collected from the moment of procedure 
initialing to that of participant discharged. Any adverse event 
occurring during the time defined as severe procedure related 
complications as death, cerebral or pulmonary embolism, device 
dislocation that required surgical removal, persistent 栿 Degree 
atrioventricular block (AVB) that required pacemaker placement 
and any event that required acute resuscitation. Any transient 
significant increase in AR and worsened cardiac dysfunction that 
required drug treatment was categorized into moderate procedure 
related complications. These events included peripheral hemorrhage 
(transient or required suspending anticoagulant therapy); transient 
complete left bundle branch block (CLBBB) and transient 栿 Degree 
AVB that required medication and monitoring were defined as mild 
procedure related complications.
  Patients were commonly discharged 3-4 days after the procedure. 
Clinical examination, echocardiography (for evaluating residual 
shunts, device position and relation to aortic and tricuspid valves, 
valvular regurgitation), chest radiography, and electrocardiography 
were performed before discharge, as well as 1, 3, 6, 12 months 
following the procedure. Until the time when performing this 
analysis, the 63 patients successfully undergoing the closure had 
been followed.
3. Results
3.1. Procedural data
  Device placement was successful in 56 cases at the first attempt 
of closure. Another 7 patients required another interventional 
replacement of occluders due to inappropriate device size. Two 
participants quitted procedure due to significant aggravation 
of device-related aortic regurgitation when attempt with a total 
immediate success rate of 96.9%.
3.2. Data of perioperative complications
  A total of 7 complications related to the procedure or device 
implantation occurred in 65 patients (10.8%). There was no death, 
cerebral or pulmonary embolism, occluder dislocation or persistent 
栿 Degree AVB occurred. Moderate complications were encountered 
in 2 patients (3.0%) because of significant aggravation of device-
related aortic regurgitation and finally their parents decided to quit 
transcatheter closure procedures. Mild complications occurred 
in 5/65 patients (7.7%). Those included postoperative peripheral 
hemorrhage in 3 patients and transient 栿 degree AVB in 2 patients. 
The latter two patients remained in sinus rhythm and required a 
prolonged course of monitoring after procedure. None of patients 
required temporary and permanent pacemaker implantation. 
3.3. Follow-up data
  At discharge, no aggravation of aortic regurgitation was detected 
in patients. Of the 63 patients who have reached the 1-year 
postprocedurual follow-up, none had trivial residual shunting 
cross defect. No cases of hemolysis, thromboembolic events, or 
endocarditis occurred. Furthermore, at one-year follow-up, grade 
of residual AR were relieved in 39 of 63 (61.9%) patients and there 
were 23 of 63 (36.5%) cases gained amelioration in grade of AVP 
(Figure 4 and 5).
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Figure 4. Comparison of severity of AR preoperatively, at discharge, and at 
one year follow-up, respectively.
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Figure 5. Comparison of severity of AVP assessed by echocardiography 
preoperatively, at discharge, and at one year follow-up, respectively.
4. Discussion
  AVP and AR are well known to be linked with VSD[5]. Subaortic 
VSD will enhance progression of AR with the incidence of 18%[6]. 
There is few studies have focused on a subset of patients with 
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subaortic VSDs combined with AVP. The development of AVP is a 
risk factor for increasing AR was also confirmed[7]. Transcatheter 
closure such defects with devices as early as possible for avoiding 
deterioration of hemodynamic situation may prove to be a valuable 
alternative. However, there still are rare reports in the literature 
provide clinical information on device closure of VSDs in patients 
with AVP and mild AR. The main reason for it was contributed to 
that the diameter of defects and a limited aortic rim could present 
a significant challenge to operator. If the left ventricular disc of 
occluder impairs leaflets of aortic valve, patients may require abort 
procedure because of significant AR. This has been reported as 
high as 6.8% and tends to spontaneously resolve with time but not 
always. Therefore, whether perform the closure or not remains 
controversial[8]. ACC/AHA Guideline also reminded that patients 
with a small VSD and AVP may not recommended as the primary 
indication for closure and high possibility of developing progressive 
AR[9]. However, confronted with this obstacle, considering that 
transcatheter closure is less invasive than surgery and believing that 
early occlusion can prevent late hemodynamic disorder of AR and 
diminish the need for surgery, we still made attempt of transcatheter 
closure for these patients and manifested a satisfactory results.
  The present study shows an excellent intermediate and perioperative 
outcome with a very high rate of success closure and a low incidence 
of complications. Here we demonstrate that when this procedure 
was successful in most of patients and only two patients exhibited 
aggravated AR. There were no severe complications related to the 
procedure. Moderate and mild complications occurred in 2 and 5 of 
the 65 patients, respectively. These results suggest that transcatheter 
closure can be performed feasibly and safely by selecting proper 
subjects and performing precisely even patients combined with 
AVP and mild AR. We have shown that the application of the 
device closure should not be limited on these patients if appropriate 
inclusion criteria were implemented. However, 2 cases with 
increasing AR imply that conventional left ventricular angiography 
and TTE sometimes may underestimate the movement of prolapsed 
aortic valve. Intraoperative cranial plus angulation projection and 
TTE in other view should be much better for showing anatomical 
and functional relationship between the retrieved occluder and 
prolapsed aortic valve, especially for patients with severe prolapsed 
aortic valve. Since the two unsuccessful percutaneous attempts 
occurred in patients, we conclude and emphasize that subaortic rim 
from VSD should be more than 3mm. Result of this series make us 
believe that preoperative elaborate evaluation of the anatomical and 
pathophysiological characteristic of defect plays a crucial role in 
avoiding unnecessary attempts in patients without proper indication. 
On the other hand, we also founded that two participants present 
with transient 栿 degree AVB. The plausible explanation for it 
should be expansion of oversized VSD occluder transiently compress 
adjacent conduction tissues and induce the local edema.
  Our series follow-up demonstrates other encouraging results with no 
progressive AR were detected in participants after hospital discharge. 
Furthermore, part of patient present gradual amelioration of AR or 
AVP. This also claim that direct closure actually improved degree of 
AVP and secondary AR. Base on general agreement of that prolapse 
of the aortic valve leaflet were the dominant factor of AR[10], 
We postulated that the potential mechanism may be (i) occluders 
supply support and change original hemodynamic configuration 
like Venturi effect is created by the left-to-right shunting through 
the VSD during early systole, which make transseptal blood stream 
directly enhancing of the distribution of tension throughout the 
leaflet, aggravate the pressure burden of the diastolic pressure; (ii) 
The edge of device offer a commissural support from subaortic 
zone to prolapsed aortic valve leaflet and prevent tendency toward 
the imbalance of that and related progressive deterioration of AR. 
Therefore, correction and maintaining the integrity and stability of 
whole structure of aortic valve zone will be the key issue of success 
in this transcatheter study. We believe that with further experience 
in performing transcatheter closure in these patients, it will be less 
prone to complications and higher success rate.
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